Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology

Table 7 Cost-effectiveness analysis of screening 12 diseases singly, presented in 2018 RMB

Diseases	Screening strategies	C	Incr. C	QALY	Incr. QALY	ICER	Ranking^a
PKU	MS/MS	410.255	203.800	74.252	0.00000	∞
PKU	IF	206.455		74.252
MSUD	MS/MS	307.502	307.314	74.256	0.0001	2,939,542	3
MSUD	Non-screening	0.188		74.256
CIT II	MS/MS	307.380	305.820	74.256	0.00002	18,133,638	8
CIT II	Non-screening	1.476		74.256
CIT I	MS/MS	306.957	305.709	74.256	0.00001	22,672,072	9
CIT I	Non-screening	1.180		74.256
HCY	MS/MS	307.007	304.463	74.256	0.00001	26,835,436	10
HCY	Non-screening	2.545		74.256
MMA	MS/MS	327.542	309.473	74.255	0.00023	1,322,605	2
MMA	Non-screening	18.069		74.255
IVA	MS/MS	308.210	305.563	74.256	0.00004	7,470,691	4
IVA	Non-screening	2.647		74.256
GA I	MS/MS	308.420	304.084	74.256	0.00002	18,017,789	7
GA I	Non-screening	4.336		74.256
PA	MS/MS	308.251	305.736	74.256	0.00004	8,728,484	5
PA	Non-screening	2.515		74.256
PCD	MS/MS	331.625	312.330	74.254	0.00028	1,108,216	1
PCD	Non-screening	19.295		74.253
MCAD	MS/MS	306.961	305.723	74.256	0.00002	16,900,643	6
MCAD	Non-screening	1.238		74.256
VLCAD	MS/MS	306.283	305.541	74.256	0.00001	28,203,412	11
VLCAD	Non-screening	0.742		74.256

^aIn the ranking of ICERs, the higher the rank, the bigger the ICER, indicating a less cost-effective screening program

ISSN: 1472-6963